Literature DB >> 26830883

New Developments in Cognitive-Behavioral Therapy for Social Anxiety Disorder.

Ulrich Stangier1.   

Abstract

Social anxiety disorder (SAD) is a highly prevalent and chronic disorder that causes considerable psychosocial impairment. This article reviews recent changes in the definition of SAD in DSM-5 and summarizes the current evidence for effective cognitive-behavioral treatments in adults, children, and adolescents. Current data suggests that cognitive-behavioral therapy (CBT) is efficacious in the treatment of this condition. Among different CBT approaches, individual cognitive therapy may be associated with the largest effect sizes. In this review, interventions targeting dysfunctional cognitive processes that contribute to the effective treatment of SAD are discussed. Some recent findings from neuroimaging research and studies on the augmentation of CBT using neuroenhancers indicate that changes in emotion regulation as well as fear extinction are important psychological mediators of positive outcome. Furthermore, internet-delivered CBT is a promising field of technological innovation that may improve access to effective treatments. Despite the availability of effective treatments, treatment-resistant SAD remains a common problem in clinical practice that requires more research efforts. Finally, potential areas for further development of CBT as well as its dissemination in health care are summarized.

Entities:  

Keywords:  Cognitive therapy; Emotion regulation; Fear extinction; Internet-delivered CBT; Neuroenhancement; Social anxiety disorder; Treatment-resistant SAD

Mesh:

Year:  2016        PMID: 26830883     DOI: 10.1007/s11920-016-0667-4

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  65 in total

Review 1.  Fear extinction and relapse: state of the art.

Authors:  Bram Vervliet; Michelle G Craske; Dirk Hermans
Journal:  Annu Rev Clin Psychol       Date:  2013       Impact factor: 18.561

2.  Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting?

Authors:  Michelle G Craske; Daniela Golinelli; Murray B Stein; Peter Roy-Byrne; Alexander Bystritsky; Cathy Sherbourne
Journal:  Psychol Med       Date:  2005-11       Impact factor: 7.723

Review 3.  Benzodiazepine discontinuation difficulties in panic disorder: conceptual model and outcome for cognitive-behavior therapy.

Authors:  M W Otto; J J Hong; S A Safren
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

4.  RETRACTED: Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies.

Authors:  Stefan G Hofmann; Angela Fang; Daniel N Brager
Journal:  Psychiatry Res       Date:  2015-06-10       Impact factor: 3.222

5.  Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder.

Authors:  Diana Koszycki; Melodie Benger; Jakov Shlik; Jacques Bradwejn
Journal:  Behav Res Ther       Date:  2007-05-03

6.  Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: a multicenter randomized controlled trial.

Authors:  Falk Leichsenring; Simone Salzer; Manfred E Beutel; Stephan Herpertz; Wolfgang Hiller; Juergen Hoyer; Johannes Huesing; Peter Joraschky; Bjoern Nolting; Karin Poehlmann; Viktoria Ritter; Ulrich Stangier; Bernhard Strauss; Nina Stuhldreher; Susan Tefikow; Tobias Teismann; Ulrike Willutzki; Joerg Wiltink; Eric Leibing
Journal:  Am J Psychiatry       Date:  2013-07       Impact factor: 18.112

Review 7.  Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders.

Authors:  Stefan G Hofmann
Journal:  Clin Psychol Rev       Date:  2007-05-03

8.  Cognitive Therapy and Task Concentration Training Applied as Intensified Group Therapies for Social Anxiety Disorder with Fear of Blushing-A Randomized Controlled Trial.

Authors:  Samia Härtling; Jens Klotsche; Anke Heinrich; Jürgen Hoyer
Journal:  Clin Psychol Psychother       Date:  2015-10-09

Review 9.  Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis.

Authors:  Dennis Ougrin
Journal:  BMC Psychiatry       Date:  2011-12-20       Impact factor: 3.630

10.  Impact of cognitive-behavioral therapy for social anxiety disorder on the neural bases of emotional reactivity to and regulation of social evaluation.

Authors:  Philippe R Goldin; Michal Ziv; Hooria Jazaieri; Justin Weeks; Richard G Heimberg; James J Gross
Journal:  Behav Res Ther       Date:  2014-08-21
View more
  5 in total

1.  Pilot randomized trial of self-guided virtual reality exposure therapy for social anxiety disorder.

Authors:  Nur Hani Zainal; William W Chan; Alisha P Saxena; Craig Barr Taylor; Michelle G Newman
Journal:  Behav Res Ther       Date:  2021-10-06

2.  Exploring the Relationship Between Interpersonal Emotion Regulation and Social Anxiety Symptoms: The Mediating Role of Negative Mood Regulation Expectancies.

Authors:  Koray Akkuş; Mehmet Peker
Journal:  Cognit Ther Res       Date:  2021-08-14

3.  Efficacy and acceptability of psychological interventions for social anxiety disorder in children and adolescents: a meta-analysis of randomized controlled trials.

Authors:  Lining Yang; Xinyu Zhou; Juncai Pu; Lanxiang Liu; Pim Cuijpers; Yuqing Zhang; Hanping Zhang; Shuai Yuan; Teng Teng; Lu Tian; Peng Xie
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-07-13       Impact factor: 4.785

4.  DJINNI: A Novel Technology Supported Exposure Therapy Paradigm for SAD Combining Virtual Reality and Augmented Reality.

Authors:  Maher Ben-Moussa; Marius Rubo; Coralie Debracque; Wolf-Gero Lange
Journal:  Front Psychiatry       Date:  2017-04-28       Impact factor: 4.157

5.  A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents.

Authors:  Marija Bogadi; Snježana Kaštelan
Journal:  Croat Med J       Date:  2021-10-31       Impact factor: 1.351

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.